These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 31796494)

  • 1. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
    Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
    EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
    Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
    BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
    Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
    Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cells-based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis.
    Okano H; Morimoto S; Kato C; Nakahara J; Takahashi S
    J Neurochem; 2023 Dec; 167(5):603-614. PubMed ID: 37952981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
    Hsyu PH; Mould DR; Upton RN; Amantea M
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
    Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
    Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
    Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
    BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial.
    Yamashita T; Nakano Y; Sasaki R; Tadokoro K; Omote Y; Yunoki T; Kawahara Y; Matsumoto N; Taira Y; Matsuoka C; Morihara R; Abe K
    Cell Transplant; 2023; 32():9636897231214370. PubMed ID: 38014622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis.
    Imamura K; Izumi Y; Watanabe A; Tsukita K; Woltjen K; Yamamoto T; Hotta A; Kondo T; Kitaoka S; Ohta A; Tanaka A; Watanabe D; Morita M; Takuma H; Tamaoka A; Kunath T; Wray S; Furuya H; Era T; Makioka K; Okamoto K; Fujisawa T; Nishitoh H; Homma K; Ichijo H; Julien JP; Obata N; Hosokawa M; Akiyama H; Kaneko S; Ayaki T; Ito H; Kaji R; Takahashi R; Yamanaka S; Inoue H
    Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
    Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
    JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
    Abbas R; Leister C; Sonnichsen D
    Clin Drug Investig; 2013 Aug; 33(8):589-95. PubMed ID: 23839484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
    Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
    Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons.
    Osaki T; Uzel SGM; Kamm RD
    Sci Adv; 2018 Oct; 4(10):eaat5847. PubMed ID: 30324134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
    Henderson RD; Agosti JM; McCombe PA; Thorpe K; Heggie S; Heshmat S; Appleby MW; Ziegelaar BW; Crowe DT; Redlich GL
    Medicine (Baltimore); 2021 Oct; 100(42):e27421. PubMed ID: 34678870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
    J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.